Birchbrook, Inc. Biomarin Pharmaceutical Inc Transaction History

Birchbrook, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jun 10, 2025	SELL	$61.93 - $70.49 $3,406 - $3,876	-55 Closed	0 $0
Q3 2024 Jun 10, 2025	SELL	$69.02 - $93.84 $548,570 - $745,840	-7,948 Reduced 99.31%	55 $3.87 Million
Q2 2024 Jun 10, 2025	SELL	$74.43 - $92.22 $22,998 - $28,495	-309 Reduced 3.72%	8,003 $659 Million
Q1 2024 Jun 10, 2025	BUY	$83.81 - $99.0 $33,104 - $39,105	395 Added 4.99%	8,312 $726 Million
Q4 2023 Jun 10, 2025	BUY	$76.22 - $98.51 $603,433 - $779,903	7,917 New	7,917 $763 Million

674

185M

1.31M

1.1M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Birchbrook, Inc., based on Form 13F filings with the SEC.

Stay updated on Birchbrook, Inc. with notifications on news.